Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Govitecan and Tagitanlimab as Neoadjuvant Therapy for Resectable HNSCC
NCT07492914Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- May 2026
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab govitecan, tagitanlimab in head and neck squamous cell carcinoma (HNSCC), sponsored by West China Hospital of Sichuan University. Started May 2026; status: recruiting.
02
Drugs
sacituzumab govitecantagitanlimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07492914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07492914.